Somewhat Positive News Coverage Somewhat Unlikely to Affect Henry Schein (HSIC) Stock Price

Press coverage about Henry Schein (NASDAQ:HSIC) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.2974717368965 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Henry Schein (NASDAQ:HSIC) opened at 82.88 on Friday. The firm has a market capitalization of $6.55 billion, a P/E ratio of 12.11 and a beta of 1.10. Henry Schein has a 1-year low of $82.16 and a 1-year high of $186.99. The company has a 50-day moving average price of $170.49 and a 200-day moving average price of $175.55.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 EPS for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.02. The business had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. On average, equities research analysts predict that Henry Schein will post $7.27 earnings per share for the current fiscal year.

HSIC has been the topic of several research reports. Credit Suisse Group reissued a “hold” rating and issued a $87.50 price objective on shares of Henry Schein in a research report on Tuesday, August 29th. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a research note on Thursday, July 6th. Piper Jaffray Companies upgraded Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday. Finally, Jefferies Group LLC restated a “hold” rating and set a $88.50 target price on shares of Henry Schein in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $93.30.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at

In other news, SVP Paul Rose sold 2,126 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the transaction, the senior vice president now owns 17,841 shares of the company’s stock, valued at $3,077,750.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.27% of the stock is currently owned by corporate insiders.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply